Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine plus adjuvant chemotherapy in high-risk endometrial cancer
ChiCTR2500109068Phase 4Not yet recruiting
- Sponsor
- International Peace Maternity and Child Health Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Placebo plus standard adjuvant therapy with Vortioxetine plus standard adjuvant therapy (2 arms). Primary endpoints: Disease-free survival (DFS) and Overall survival (OS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
vortioxetine
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on ChiCTR2500109068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109068.